 Corey Lyon
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 201 | 1.230 |
Why?
| | Hypertension | 4 | 2022 | 1052 | 0.990 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 212 | 0.980 |
Why?
| | Glucocorticoids | 3 | 2018 | 526 | 0.890 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 213 | 0.870 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 61 | 0.840 |
Why?
| | Medical Staff | 2 | 2022 | 16 | 0.840 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 261 | 0.840 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 907 | 0.800 |
Why?
| | Metformin | 2 | 2023 | 274 | 0.790 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 305 | 0.750 |
Why?
| | Sphygmomanometers | 1 | 2021 | 5 | 0.750 |
Why?
| | Insulin, Isophane | 1 | 2021 | 17 | 0.740 |
Why?
| | Automation | 1 | 2021 | 74 | 0.730 |
Why?
| | Employment | 1 | 2022 | 137 | 0.720 |
Why?
| | Insulin Glargine | 1 | 2021 | 72 | 0.720 |
Why?
| | Humans | 53 | 2023 | 114045 | 0.720 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1471 | 0.710 |
Why?
| | Prediabetic State | 1 | 2023 | 219 | 0.710 |
Why?
| | Aspirin | 2 | 2020 | 324 | 0.700 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 122 | 0.700 |
Why?
| | Preventive Health Services | 1 | 2022 | 134 | 0.700 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 17 | 0.690 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 20 | 0.690 |
Why?
| | Ganglion Cysts | 1 | 2020 | 9 | 0.670 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 154 | 0.670 |
Why?
| | Papillomaviridae | 1 | 2020 | 101 | 0.670 |
Why?
| | C-Reactive Protein | 2 | 2021 | 362 | 0.660 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2087 | 0.660 |
Why?
| | Wrist | 1 | 2020 | 47 | 0.650 |
Why?
| | Spironolactone | 1 | 2019 | 27 | 0.640 |
Why?
| | Memory | 1 | 2021 | 209 | 0.640 |
Why?
| | Diuretics | 1 | 2019 | 64 | 0.640 |
Why?
| | Probiotics | 1 | 2019 | 48 | 0.630 |
Why?
| | Ketorolac | 1 | 2019 | 16 | 0.630 |
Why?
| | Glucosamine | 1 | 2018 | 12 | 0.620 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 296 | 0.620 |
Why?
| | Erythromycin | 1 | 2018 | 25 | 0.610 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 11 | 0.600 |
Why?
| | Acute Pain | 1 | 2019 | 35 | 0.600 |
Why?
| | Glycemic Index | 1 | 2018 | 20 | 0.600 |
Why?
| | Sweating | 1 | 2018 | 23 | 0.600 |
Why?
| | Viscosupplements | 1 | 2018 | 9 | 0.590 |
Why?
| | Ureteral Calculi | 1 | 2018 | 13 | 0.590 |
Why?
| | Patient Education as Topic | 2 | 2022 | 666 | 0.580 |
Why?
| | Testosterone | 1 | 2021 | 341 | 0.570 |
Why?
| | Musculoskeletal System | 1 | 2018 | 42 | 0.570 |
Why?
| | Hot Flashes | 1 | 2018 | 72 | 0.570 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 95 | 0.570 |
Why?
| | Telemedicine | 2 | 2022 | 662 | 0.550 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 33 | 0.550 |
Why?
| | Hypoglycemia | 1 | 2021 | 386 | 0.540 |
Why?
| | Athletic Injuries | 1 | 2023 | 456 | 0.540 |
Why?
| | Family Practice | 2 | 2018 | 426 | 0.540 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 163 | 0.540 |
Why?
| | Labor, Obstetric | 1 | 2017 | 52 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1204 | 0.540 |
Why?
| | Warfarin | 1 | 2017 | 136 | 0.540 |
Why?
| | Analgesics | 1 | 2018 | 156 | 0.530 |
Why?
| | Melatonin | 1 | 2017 | 106 | 0.530 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 138 | 0.530 |
Why?
| | Job Satisfaction | 1 | 2018 | 168 | 0.530 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1381 | 0.530 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 189 | 0.520 |
Why?
| | Migraine Disorders | 1 | 2017 | 82 | 0.510 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 27 | 0.510 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 101 | 0.510 |
Why?
| | Brain Concussion | 1 | 2023 | 477 | 0.510 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 254 | 0.500 |
Why?
| | Methylprednisolone | 1 | 2016 | 80 | 0.500 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 592 | 0.500 |
Why?
| | Menopause | 1 | 2018 | 271 | 0.480 |
Why?
| | Mass Screening | 2 | 2022 | 979 | 0.480 |
Why?
| | Patient Care Team | 2 | 2018 | 517 | 0.460 |
Why?
| | Exercise Therapy | 1 | 2018 | 351 | 0.460 |
Why?
| | Cough | 1 | 2015 | 107 | 0.460 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 139 | 0.430 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 325 | 0.430 |
Why?
| | Antioxidants | 1 | 2017 | 529 | 0.430 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 493 | 0.430 |
Why?
| | Anticoagulants | 1 | 2017 | 547 | 0.420 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 16 | 0.420 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 11 | 0.420 |
Why?
| | Behavior Therapy | 3 | 2023 | 225 | 0.410 |
Why?
| | Virus Diseases | 1 | 2015 | 195 | 0.410 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 1726 | 0.390 |
Why?
| | Health Promotion | 1 | 2018 | 675 | 0.390 |
Why?
| | Low Back Pain | 2 | 2023 | 93 | 0.380 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6306 | 0.370 |
Why?
| | Pain Measurement | 4 | 2023 | 441 | 0.350 |
Why?
| | Aged | 10 | 2021 | 18969 | 0.340 |
Why?
| | Depression | 1 | 2017 | 1133 | 0.320 |
Why?
| | Female | 16 | 2023 | 59324 | 0.320 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 122 | 0.300 |
Why?
| | Pregnancy | 4 | 2022 | 5499 | 0.300 |
Why?
| | Middle Aged | 11 | 2021 | 26605 | 0.300 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 222 | 0.290 |
Why?
| | Organizational Innovation | 2 | 2019 | 132 | 0.280 |
Why?
| | Treatment Outcome | 7 | 2021 | 9049 | 0.280 |
Why?
| | Abdomen, Acute | 1 | 2006 | 17 | 0.270 |
Why?
| | Azithromycin | 2 | 2018 | 80 | 0.270 |
Why?
| | Enuresis | 1 | 2005 | 3 | 0.260 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 10 | 0.250 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.250 |
Why?
| | Adult | 9 | 2022 | 30375 | 0.250 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 76 | 0.220 |
Why?
| | Age Factors | 2 | 2022 | 2885 | 0.210 |
Why?
| | Fibromyalgia | 1 | 2023 | 55 | 0.210 |
Why?
| | Naltrexone | 1 | 2023 | 82 | 0.200 |
Why?
| | Electronics | 1 | 2023 | 66 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 1836 | 0.200 |
Why?
| | United States | 5 | 2022 | 12137 | 0.200 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 662 | 0.200 |
Why?
| | Occult Blood | 1 | 2022 | 24 | 0.200 |
Why?
| | Time Factors | 2 | 2023 | 6077 | 0.190 |
Why?
| | Postmenopause | 1 | 2023 | 301 | 0.180 |
Why?
| | Life Style | 1 | 2023 | 428 | 0.180 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.180 |
Why?
| | Fish Oils | 1 | 2020 | 21 | 0.180 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 34 | 0.180 |
Why?
| | Labor Stage, Second | 1 | 2020 | 3 | 0.180 |
Why?
| | Prenatal Care | 1 | 2022 | 250 | 0.180 |
Why?
| | Colonoscopy | 1 | 2022 | 197 | 0.170 |
Why?
| | Male | 9 | 2021 | 55396 | 0.170 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 66 | 0.170 |
Why?
| | Pain Management | 2 | 2023 | 285 | 0.160 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 118 | 0.160 |
Why?
| | Primary Health Care | 2 | 2019 | 1502 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 282 | 0.160 |
Why?
| | Ticlopidine | 1 | 2019 | 54 | 0.160 |
Why?
| | Systems Integration | 1 | 2018 | 38 | 0.160 |
Why?
| | Clostridium Infections | 1 | 2019 | 54 | 0.150 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.150 |
Why?
| | Primary Prevention | 1 | 2020 | 172 | 0.150 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 33 | 0.150 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 11 | 0.150 |
Why?
| | Netherlands | 1 | 2018 | 64 | 0.150 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 94 | 0.150 |
Why?
| | Arthralgia | 1 | 2018 | 46 | 0.150 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 103 | 0.150 |
Why?
| | Citalopram | 1 | 2018 | 28 | 0.150 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 41 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2018 | 30 | 0.150 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 38 | 0.150 |
Why?
| | Yoga | 1 | 2018 | 28 | 0.150 |
Why?
| | Patients | 1 | 2019 | 163 | 0.150 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 139 | 0.140 |
Why?
| | Sleep | 1 | 2022 | 631 | 0.140 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 116 | 0.140 |
Why?
| | Dietary Supplements | 1 | 2020 | 459 | 0.140 |
Why?
| | Recurrence | 1 | 2020 | 925 | 0.140 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 373 | 0.140 |
Why?
| | Pain | 2 | 2023 | 701 | 0.140 |
Why?
| | Regression Analysis | 1 | 2019 | 945 | 0.140 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 44 | 0.140 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 68 | 0.130 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 229 | 0.130 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 43 | 0.130 |
Why?
| | Burnout, Professional | 2 | 2019 | 323 | 0.130 |
Why?
| | Psychiatry | 1 | 2018 | 154 | 0.130 |
Why?
| | Hemorrhage | 1 | 2020 | 600 | 0.130 |
Why?
| | Exanthema | 1 | 2016 | 74 | 0.130 |
Why?
| | Prednisone | 1 | 2016 | 229 | 0.130 |
Why?
| | Administration, Oral | 1 | 2018 | 725 | 0.130 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 395 | 0.120 |
Why?
| | Injections | 1 | 2016 | 160 | 0.120 |
Why?
| | Acute Disease | 1 | 2018 | 907 | 0.120 |
Why?
| | Health Status | 1 | 2020 | 716 | 0.120 |
Why?
| | Diabetic Foot | 1 | 2015 | 22 | 0.120 |
Why?
| | Young Adult | 2 | 2023 | 10444 | 0.120 |
Why?
| | Achilles Tendon | 1 | 2015 | 38 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2019 | 572 | 0.120 |
Why?
| | Pandemics | 1 | 2022 | 1310 | 0.120 |
Why?
| | Sulfonamides | 1 | 2018 | 444 | 0.120 |
Why?
| | Tendon Injuries | 1 | 2015 | 75 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2018 | 1656 | 0.110 |
Why?
| | Gestational Age | 1 | 2017 | 761 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 230 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 949 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 330 | 0.110 |
Why?
| | Psychometrics | 1 | 2017 | 608 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2015 | 105 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2020 | 754 | 0.110 |
Why?
| | Administration, Inhalation | 1 | 2015 | 637 | 0.110 |
Why?
| | Colorado | 2 | 2019 | 4090 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 889 | 0.090 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 36 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 1011 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1815 | 0.070 |
Why?
| | Prospective Studies | 1 | 2018 | 6195 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4595 | 0.060 |
Why?
| | Adolescent | 1 | 2023 | 17800 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3039 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 278 | 0.060 |
Why?
| | Blood Pressure | 2 | 2022 | 1531 | 0.050 |
Why?
| | Amitriptyline | 1 | 2023 | 20 | 0.050 |
Why?
| | Trigger Points | 1 | 2023 | 13 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1331 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 926 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 8 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 428 | 0.040 |
Why?
| | Long-Term Care | 1 | 2019 | 77 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 140 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 132 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 183 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 714 | 0.030 |
Why?
| | Skin | 1 | 2020 | 653 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1206 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 32 | 0.030 |
Why?
| | Child | 2 | 2022 | 18401 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 96 | 0.030 |
Why?
| | Mental Health Services | 1 | 2018 | 316 | 0.030 |
Why?
| | Foot | 1 | 2015 | 103 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1447 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 544 | 0.030 |
Why?
| | Blood Glucose | 1 | 2022 | 1827 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2247 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 803 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 3315 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 944 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1690 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 2958 | 0.020 |
Why?
| | Infant | 1 | 2022 | 7943 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 8614 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|